CP-615,003 is a drug which acts as a subtype-selective partial agonist at GABAA receptors, and was developed by Pfizer as a potential anxiolytic; however, poor blood–brain barrier penetration make it primarily useful as a research ligand.
References
Bron en licentie
Gebaseerd op: Wikipedia — CP-615,003 · auteursgeschiedenis.
Tekst: CC BY-SA 4.0.
Over de bewerking
Wikisyntaxis en sjablonen zijn verwijderd; langere teksten zijn ingekort.